Incyte Corporation reported that the U.S. Food and Drug Administration pushed back the review of the company’s supplemental New Drug Application for Opzelura (ruxolitinib cream) for vitiligo.

Incyte Corp. said on May 17 the company’s ruxolitinib cream to treat pigmentation disorder vitiligo met the main goal in a late-stage study.

Boston Pharmaceuticals licenses a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.